BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11039189)

  • 1. Convenient procedures for synthesis of ciproxifan, a histamine H3-receptor antagonist.
    Stark H
    Arch Pharm (Weinheim); 2000 Sep; 333(9):315-6. PubMed ID: 11039189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists.
    Stark H; Ligneau X; Sadek B; Ganellin CR; Arrang JM; Schwartz JC; Schunack W
    Bioorg Med Chem Lett; 2000 Oct; 10(20):2379-82. PubMed ID: 11055360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-[(1H-imidazol-4-yl) methyl] benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor.
    Aslanian R; Brown JE; Shih NY; wa Mutahi M; Green MJ; She S; Del Prado M; West R; Hey J
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2263-8. PubMed ID: 9873525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A scalable synthesis of a histamine H3 receptor antagonist.
    Mani NS; Jablonowski JA; Jones TK
    J Org Chem; 2004 Nov; 69(23):8115-7. PubMed ID: 15527300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel histamine H(3)-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds.
    Stark H; Sadek B; Krause M; Hüls A; Ligneau X; Ganellin CR; Arrang JM; Schwartz JC; Schunack W
    J Med Chem; 2000 Oct; 43(21):3987-94. PubMed ID: 11052804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
    Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
    Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
    J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
    Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
    J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzophenone derivatives and related compounds as potent histamine H3-receptor antagonists and potential PET/SPECT ligands.
    Sasse A; Ligneau X; Sadek B; Elz S; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    Arch Pharm (Weinheim); 2001 Feb; 334(2):45-52. PubMed ID: 11268774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and histamine H3 receptor activity of 4-(n-alkyl)-1H-imidazoles and 4-(omega-phenylalkyl)-1H-imidazoles.
    De Esch IJ; Gaffar A; Menge WM; Timmerman H
    Bioorg Med Chem; 1999 Dec; 7(12):3003-9. PubMed ID: 10658607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New histamine H(3)-receptor ligands of the proxifan series: imoproxifan and other selective antagonists with high oral in vivo potency.
    Sasse A; Sadek B; Ligneau X; Elz S; Pertz HH; Luger P; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2000 Aug; 43(17):3335-43. PubMed ID: 10966752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of FUB 181, a selective histamine H3-receptor antagonist of high oral in vivo potency with 4-(omega-(arylalkyloxy)alkyl)-1H-imidazole structure.
    Stark H; Hüls A; Ligneau X; Purand K; Pertz H; Arrang JM; Schwartz JC; Schunack W
    Arch Pharm (Weinheim); 1998 Jun; 331(6):211-8. PubMed ID: 9713254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template.
    Aslanian R; Mutahi MW; Shih NY; McCormick KD; Piwinski JJ; Ting PC; Albanese MM; Berlin MY; Zhu X; Wong SC; Rosenblum SB; Jiang Y; West R; She S; Williams SM; Bryant M; Hey JA
    Bioorg Med Chem Lett; 2002 Mar; 12(6):937-41. PubMed ID: 11958998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.
    Ali SM; Tedford CE; Gregory R; Handley MK; Yates SL; Hirth WW; Phillips JG
    J Med Chem; 1999 Mar; 42(5):903-9. PubMed ID: 10072687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H(3)-receptor antagonists.
    Grassmann S; Sadek B; Ligneau X; Elz S; Ganellin CR; Arrang JM; Schwartz JC; Stark H; Schunack W
    Eur J Pharm Sci; 2002 May; 15(4):367-78. PubMed ID: 11988398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists.
    Meier G; Apelt J; Reichert U; Grassmann S; Ligneau X; Elz S; Leurquin F; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Eur J Pharm Sci; 2001 Jun; 13(3):249-59. PubMed ID: 11384847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists.
    Ganellin CR; Fkyerat A; Bang-Andersen B; Athmani S; Tertiuk W; Garbarg M; Ligneau X; Schwartz JC
    J Med Chem; 1996 Sep; 39(19):3806-13. PubMed ID: 8809168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.